Cargando…

Effect of Targeted Agents on the Endocrine Response of Breast Cancer in the Neoadjuvant Setting: A Systematic Review

Inhibition of aberrantly activated pathways cross-talking with hormone receptor (HR) improves response to endocrine therapy in patients with HR-positive advanced breast cancer. We performed a Pubmed database systematic review to ascertain the existence of a better clinical response when combining en...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grassadonia, Antonino, Caporale, Marta, Tinari, Nicola, Zilli, Marinella, DeTursi, Michele, Gamucci, Teresa, Vici, Patrizia, Natoli, Clara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4439944/ https://www.ncbi.nlm.nih.gov/pubmed/26000050 http://dx.doi.org/10.7150/jca.11566

Ejemplares similares

A Case of Stage I Vulvar Squamous Cell Carcinoma with Early Relapse and Rapid Disease Progression
por: Peri, Marta, et al.
Publicado: (2019)

Breast cancer follow-up strategies in randomized phase III adjuvant clinical trials: a systematic review
por: Sperduti, Isabella, et al.
Publicado: (2013)

Breast Cancer “Tailored Follow-up” in Italian Oncology Units: A Web-Based Survey
por: Natoli, Clara, et al.
Publicado: (2014)

Long-Term Outcome of Neoadjuvant Endocrine Therapy with Aromatase Inhibitors in Elderly Women with Hormone Receptor-Positive Breast Cancer
por: Grassadonia, Antonino, et al.
Publicado: (2014)

Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer
por: Natoli, Clara, et al.
Publicado: (2013)

Is the skin a sanctuary for breast cancer cells during treatment with anti-HER2 antibodies?
por: Graziano, Vincenzo, et al.
Publicado: (2015)

Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials
por: Grassadonia, Antonino, et al.
Publicado: (2018)

Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice
por: Angelucci, Domenico, et al.
Publicado: (2012)

Prognostic Relevance of Neutrophil to Lymphocyte Ratio (NLR) in Luminal Breast Cancer: A Retrospective Analysis in the Neoadjuvant Setting
por: Grassadonia, Antonino, et al.
Publicado: (2021)

Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: a retrospective multicenter study
por: Grassadonia, Antonino, et al.
Publicado: (2019)

Neoadjuvant Immune-Checkpoint Blockade in Triple-Negative Breast Cancer: Current Evidence and Literature-Based Meta-Analysis of Randomized Trials
por: Marinelli, Daniele, et al.
Publicado: (2020)

Alectinib Induced Regression of Renal and Hepatic Cysts Caused by Crizotinib
por: Di Marino, Pietro, et al.
Publicado: (2020)

Neoadjuvant Endocrine Therapy in Breast Cancer: Current Knowledge and Future Perspectives
por: Barchiesi, Giacomo, et al.
Publicado: (2020)

Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies
por: Grassadonia, Antonino, et al.
Publicado: (2013)

Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial
por: Moscetti, Luca, et al.
Publicado: (2017)

Circulating Autoantibodies to LGALS3BP: A Novel Biomarker for Cancer
por: Grassadonia, Antonino, et al.
Publicado: (2013)

Tgf-β1 transcriptionally promotes 90K expression: possible implications for cancer progression
por: Grassadonia, Antonino, et al.
Publicado: (2021)

Correction: Tgf-β1 transcriptionally promotes 90K expression: possible implications for cancer progression
por: Grassadonia, Antonino, et al.
Publicado: (2021)

Prognostic relevance of DNA damage and repair biomarkers in elderly patients with hormone-receptor-positive breast cancer treated with neoadjuvant hormone therapy: evidence from the real-world setting
por: Di Benedetto, Anna, et al.
Publicado: (2019)

Skin toxicity evaluation in patients treated with cetuximab for metastatic colorectal cancer: a new tool for more accurate comprehension of quality of life impacts
por: De Tursi, Michele, et al.
Publicado: (2017)

Pancytopenia During Osimertinib Treatment in a Patient with EGFR-Mutated Non-Small Cell Lung Cancer
por: Di Marino, Pietro, et al.
Publicado: (2022)

Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells
por: Veschi, Serena, et al.
Publicado: (2018)

Prognostic value of gender and primary tumor location in metastatic colon cancer
por: Grassadonia, Antonino, et al.
Publicado: (2023)

Eribulin in Triple Negative Metastatic Breast Cancer: Critic Interpretation of Current Evidence and Projection for Future Scenarios
por: Pizzuti, Laura, et al.
Publicado: (2019)

Topographic expression of the Hippo transducers TAZ and YAP in triple-negative breast cancer treated with neoadjuvant chemotherapy
por: Vici, Patrizia, et al.
Publicado: (2016)

MicroRNA-based signatures impacting clinical course and biology of ovarian cancer: a miRNOmics study
por: Krasniqi, E., et al.
Publicado: (2021)

The Hippo transducer TAZ as a biomarker of pathological complete response in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapy
por: Vici, Patrizia, et al.
Publicado: (2014)

Analysis of systemic inflammatory biomarkers in neuroendocrine carcinomas of the lung: prognostic and predictive significance of NLR, LDH, ALI, and LIPI score
por: Galvano, Antonio, et al.
Publicado: (2020)

Anthropometric, clinical and molecular determinants of treatment outcomes in postmenopausal, hormone receptor positive metastatic breast cancer patients treated with fulvestrant: Results from a real word setting
por: Pizzuti, Laura, et al.
Publicado: (2017)

Predictive significance of DNA damage and repair biomarkers in triple-negative breast cancer patients treated with neoadjuvant chemotherapy: An exploratory analysis
por: Vici, Patrizia, et al.
Publicado: (2015)

Optimizing the Choice for Adjuvant Chemotherapy in Gastric Cancer
por: Grassadonia, Antonino, et al.
Publicado: (2022)

Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study
por: Vici, Patrizia, et al.
Publicado: (2014)

The Role of Dysfunctional Adipose Tissue in Pancreatic Cancer: A Molecular Perspective
por: Brocco, Davide, et al.
Publicado: (2020)

High Blood Concentration of Leukocyte-Derived Extracellular Vesicles Is Predictive of Favorable Clinical Outcomes in Patients with Pancreatic Cancer: Results from a Multicenter Prospective Study
por: Brocco, Davide, et al.
Publicado: (2022)

Neoadjuvant Endocrine Therapy (NET) in breast cancer – COVID setting
por: Bardoli, Antonio, et al.
Publicado: (2022)

Blood Circulating CD133+ Extracellular Vesicles Predict Clinical Outcomes in Patients with Metastatic Colorectal Cancer
por: Brocco, Davide, et al.
Publicado: (2022)

Non-Pegylated Liposomal Doxorubicin-Cyclophosphamide in Sequential Regimens with Taxanes as Neoadjuvant Chemotherapy in Breast Cancer Patients
por: Vici, Patrizia, et al.
Publicado: (2014)

Drug Repurposing, an Attractive Strategy in Pancreatic Cancer Treatment: Preclinical and Clinical Updates
por: De Lellis, Laura, et al.
Publicado: (2021)

Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The PRACTICE study
por: Bersanelli, Melissa, et al.
Publicado: (2020)

Meta-analysis of phase III trials of docetaxel alone or in combination with chemotherapy in metastatic breast cancer
por: Belfiglio, Maurizio, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_dfbhnfl4osaoa2klo60j8umlkj